PLx Pharma Inc (PLXP):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:PLx Pharma Inc (PLXP) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C7581
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:36
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
PLx Pharma Inc (PLx Pharma) is a pharmaceutical company that develops patent-protected delivery systems. The company offers products such as PLxGuard delivery system, PLxGuard pipeline products, and PL1100 and PL1200 ibuprofen products. Its PLxGuard delivery system are used in enhancement of efficacy of drugs, GI safety development, new or extended patent protection, and new drug application solutions. PLx Pharma’s lead product candidate include Aspertec 325 mg, which is a novel formulations of aspirin that uses PLxGuard delivery system to reduce acute gastrointestinal side effects while providing antiplatelet effectiveness for cardiovascular disease prevention. It also offers publications and research services. The company serves healthcare professionals. PLx Pharma is headquartered in Houston, Texas, the US.

PLx Pharma Inc (PLXP) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
PLx Pharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
PLx Pharma Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
PLx Pharma Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
PLx Pharma Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
PLx Pharma Inc, Medical Devices Deals, 2012 to YTD 2018 9
PLx Pharma Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
PLx Pharma Inc, Pharmaceuticals & Healthcare, Deal Details 11
Venture Financing 11
PLx Pharma Raises USD1.3 Million in Venture Financing 11
PLx Pharma Raises USD9 Million in Extended Series E Financing 12
PLx Pharma Raises USD8.27 Million in Series E Financing 13
Merger 14
Dipexium Pharma Merges with PLx Pharma 14
Licensing Agreements 16
PLx Pharma Enters into Licensing Agreement with Lee’s Pharma for Cardiovascular Product 16
Equity Offering 18
PLx Pharma Raises USD18.2 Million in Private Placement of Shares 18
PLx Pharma Withdraws IPO 20
PLx Pharma Inc – Key Competitors 22
PLx Pharma Inc – Key Employees 23
PLx Pharma Inc – Locations And Subsidiaries 24
Head Office 24
Other Locations & Subsidiaries 24
Recent Developments 25
Financial Announcements 25
Aug 10, 2018: PLx Pharma reports second quarter 2018 results 25
May 11, 2018: PLx Pharma Inc. Reports First Quarter 2018 Results 27
May 11, 2018: PLx Pharma Reports First Quarter 2018 Results 28
Mar 23, 2018: PLx Pharma Reports Fourth Quarter and Full Year 2017 Results 29
Nov 09, 2017: PLx Pharma Reports Third Quarter 2017 Results 31
Aug 10, 2017: PLx Pharma Reports Second Quarter 2017 Results 33
May 02, 2017: Rita M. O Connor Appointed Chief Financial Officer of PLx Pharma 34
Corporate Communications 35
May 01, 2017: PLx Pharma appoints vice president of sales and marketing 35
Appendix 36
Methodology 36
About GlobalData 36
Contact Us 36
Disclaimer 36

List of Tables
PLx Pharma Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
PLx Pharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
PLx Pharma Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
PLx Pharma Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
PLx Pharma Inc, Deals By Therapy Area, 2012 to YTD 2018 8
PLx Pharma Inc, Medical Devices Deals, 2012 to YTD 2018 9
PLx Pharma Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
PLx Pharma Raises USD1.3 Million in Venture Financing 11
PLx Pharma Raises USD9 Million in Extended Series E Financing 12
PLx Pharma Raises USD8.27 Million in Series E Financing 13
Dipexium Pharma Merges with PLx Pharma 14
PLx Pharma Enters into Licensing Agreement with Lee's Pharma for Cardiovascular Product 16
PLx Pharma Raises USD18.2 Million in Private Placement of Shares 18
PLx Pharma Withdraws IPO 20
PLx Pharma Inc, Key Competitors 22
PLx Pharma Inc, Key Employees 23
PLx Pharma Inc, Other Locations 24

List of Figures
PLx Pharma Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
PLx Pharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
PLx Pharma Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
PLx Pharma Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
PLx Pharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
PLx Pharma Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
PLx Pharma Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
PLx Pharma Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
PLx Pharma Inc, Medical Devices Deals, 2012 to YTD 2018 9

★海外企業調査レポート[PLx Pharma Inc (PLXP):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Biocodex Inc-製薬・医療分野:企業M&A・提携分析
    Summary Biocodex Inc (Biocodex), a subsidiary of Biocodex is a manufacturer and distributor probiotic drug products. The company’s products include Saccharomyces boulardii CNCM I-745 that has a positive effect on the gut's microflora. It also provides Florastor, a yeast-based probiotic that helps ke …
  • Mundipharma International Ltd:製薬・医療:M&Aディール及び事業提携情報
    Summary Mundipharma International Ltd (Mundipharma) engages in the research and development of products for the treatment pain management, respiratory, cancer and inflammatory conditions. The company commercializes and launches products within Europe and rest of the world. Mundipharma offers its pro …
  • Swisscom, Ltd.:企業の戦略・SWOT・財務情報
    Swisscom, Ltd. - Strategy, SWOT and Corporate Finance Report Summary Swisscom, Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpora …
  • MacroGenics Inc (MGNX):企業の財務・戦略的SWOT分析
    MacroGenics Inc (MGNX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses an …
  • Manhattan Associates Inc (MANH):企業の財務・戦略的SWOT分析
    Manhattan Associates Inc (MANH) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weak …
  • ArQule Inc (ARQL):製薬・医療:M&Aディール及び事業提携情報
    Summary ArQule Inc (ArQule) is a development stage clinical biotechnology company. It carries out discovery and development of next-generation, small molecule therapeutics for the treatment of various types of cancer. ArQule develops its oncology product candidates through novel approaches including …
  • Dompe Farmaceutici SpA:製薬・医療:M&Aディール及び事業提携情報
    Summary Dompe Farmaceutici SpA (Dompe) is a developer of therapeutic solutions that research novel therapies for the treatment of rare and orphan diseases. The company provides product pipeline such as C5aR Antagonists, TRPM8 Blockers pain, TRPM8 Blockers urology, BKB1R Antagonists, CNR2 Agonists an …
  • Nordic Nanovector ASA (NANO):企業の財務・戦略的SWOT分析
    Summary Nordic Nanovector ASA (Nordic Nanovector), formerly Nordic Nanovector AS is a developer and commercializer of antibody radionuclide conjugates for the treatment of haematological cancers. The company’s lead product candidate includes Betalutin, an antibody radionuclide conjugate developed fo …
  • PolyPid Ltd-医療機器分野:企業M&A・提携分析
    Summary PolyPid Ltd (PolyPid) is a clinical stage pharmaceutical company that develops, manufactures and commercialize drugs for extended release and local delivery. The company develops its products using PLEX (Polymer-Lipid Encapsulation MatriX) platform, which helps in products. PolyPid’s pipelin …
  • Innergex Renewable Energy Inc (INE):電力:M&Aディール及び事業提携情報
    Summary Innergex Renewable Energy Inc (Innergex) is an independent renewable power producer. It develops, acquires, owns and operates hydroelectric facilities, wind farms, and solar photovoltaic geothermal power facilities. Through long-term power purchase agreements, the company sells electricity t …
  • Cantargia AB (CANTA):企業の財務・戦略的SWOT分析
    Summary Cantargia AB (Cantargia), a subsidiary of Lund University Bioscience AB is a biotechnology company that develops antibody based cancer treatments. The company’s product candidate CAN04 is used for the treatment of cancers including non-small cell lung cancer and pancreatic cancer. It utilize …
  • China Yurun Food Group Limited:企業の戦略・SWOT・財務情報
    China Yurun Food Group Limited - Strategy, SWOT and Corporate Finance Report Summary China Yurun Food Group Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product a …
  • Enercon GmbH:企業の戦略的SWOT分析
    Enercon GmbH - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. …
  • Brodrene Hartmann AS:戦略・SWOT・企業財務分析
    Brodrene Hartmann AS - Strategy, SWOT and Corporate Finance Report Summary Brodrene Hartmann AS - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • amcure GmbH:製薬・医療:M&Aディール及び事業提携情報
    Summary Amcure GmbH (Amcure) is a biopharmaceutical company that discovers and develops therapeutics for the treatment of cancer. The company develops peptide-based compounds for the treatment of metastatic forms of cancer. Its lead candidate, AMC303 is used for the treatment of metastatic epithelia …
  • The Law Debenture Corp plc (LWDB):企業の財務・戦略的SWOT分析
    Summary The Law Debenture Corp plc (LDC) is a financial service provider that offers investment trust and independent fiduciary services. The company’s services include corporate trusts, pension trusteeship, whistle blowing services and governance services. It offers financial services such as trust …
  • Novotech (Australia) Pty Ltd:製薬・医療:M&Aディール及び事業提携情報
    Summary Novotech (Australia) Pty Ltd (Novotech) is a contract research organization that offers clinical development services. The organization’s services include clinical trials, data management, biostatistics analysis, audits, regulatory affairs, medical writing, site management and commercializat …
  • Ssr Mining Inc
    Ssr Mining Inc - Strategy, SWOT and Corporate Finance Report Summary Ssr Mining Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpora …
  • China Agri-Industries Holdings Ltd (606):企業の財務・戦略的SWOT分析
    China Agri-Industries Holdings Ltd (606) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths …
  • AnGes Inc (4563):製薬・医療:M&Aディール及び事業提携情報
    Summary AnGes Inc (AnGes) is a biopharmaceutical company which discovers and develops gene and nucleotide based drugs and reagents for use in functional analysis of genetic medication. The company specializes in research and development (R&D) and practical application of genetic medicine. It has two …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆